Table 4.
Parameter | Groups | 2-Year CSS (%) | 5-Year CSS (%) | 10-Year CSS (%) | χ2 Test-Value | p-value |
---|---|---|---|---|---|---|
Age | 19–49 | 82 | 75 | 75 | 3.037 | 0.386 |
50–61 | 89 | 81 | 20 | |||
62–70 | 84 | 73 | 22 | |||
71–88 | 73 | 40 | 40 | |||
Gender | Female | 80 | 64 | 35 | 0.956 | 0.339 |
Male | 84 | 73 | 52 | |||
WHO | 0 | 94 | 86 | 86 | 19.412 | <0.001 |
1 | 80 | 68 | 27 | |||
2 | 50 | 11 | 0 | |||
3 | 0 | 0 | 0 | |||
Location | Parotid | 83 | 62 | 36 | 1.068 | 0.285 |
Submandibular | 81 | 75 | 50 | |||
Clinical nerve palsy | Yes | 61 | 47 | 38 | 2.292 | 0.021 |
No | 89 | 75 | 41 | |||
Radicality | R0 | 84 | 69 | 43 | 1.444 | 0.485 |
R1 | 79 | 69 | 43 | |||
R2 | 90 | 72 | 36 | |||
Nerve palsy after surgery | Yes | 66 | 46 | 33 | 2.740 | 0.006 |
No | 88 | 77 | 42 | |||
Histopathological type | Squamous | 64 | 55 | 0 | 6.758 | 0.239 |
Adenocarcinoma | 94 | 69 | 37 | |||
Cystic adenoid carcinoma | 82 | 74 | 37 | |||
Undifferentiated | 80 | 60 | 30 | |||
Acinic | 100 | 87 | 65 | |||
Other | 83 | 72 | 72 | |||
Neuroinvasion | Yes | 73 | 54 | 36 | 2.050 | 0.040 |
No | 86 | 75 | 45 | |||
Angioinvasion | Yes | 68 | 50 | 50 | 1.390 | 0.164 |
No | 85 | 71 | 43 | |||
Stage | I | 100 | 100 | 80 | 16.118 | 0.001 |
II | 92 | 79 | 48 | |||
III | 74 | 74 | 38 | |||
IVab | 74 | 43 | 37 | |||
T | 1 | 100 | 100 | 80 | 22.324 | <0.001 |
2 | 91 | 78 | 49 | |||
3 | 76 | 66 | 34 | |||
4 | 62 | 33 | 33 | |||
N | Positive | 67 | 43 | 23 | 3.511 | <0.001 |
Negative | 89 | 79 | 51 | |||
Time | <9 weeks | 85 | 73 | 54 | 1.444 | 0.146 |
≥9 weeks | 79 | 61 | 28 | |||
Technique of RT | 2D | 53 | 25 | 25 | 3.718 | 0.004 |
3D | 81 | 73 | 50 | |||
IMRT | 90 | 76 | 36 | |||
Dose | <60Gy | 50 | 37 | 13 | 11.013 | <0.001 |
≥60Gy | 89 | 75 | 49 | |||
CHT | Yes | 82 | 68 | 34 | 0.489 | 0.625 |
No | 82 | 68 | 42 | |||
Hemoglobin level | <12.5 mg/dL | 64 | 64 | N/A | 1.016 | 0.310 |
≥12.5 mg/dL | 86 | 75 | N/A | |||
Tumor volume | ≤ 10 cm3 | 100 | 100 | 80 | 9.572 | 0.022 |
10.1–50 cm3 | 92 | 73 | N/A | |||
50.1–100 cm3 | 85 | 64 | 24 | |||
>100 cm3 | 64 | 51 | N/A | |||
Irradiation area | Only surgical bed with margin | 91 | 77 | 66 | 17.747 | <0.001 |
Surgical bed + lnd. group I–II | 92 | 74 | N/A | |||
Surgical bed + unilateral lnd. | 86 | 78 | 39 | |||
Surgical bed + bilateral lnd | 56 | 30 | 10 | |||
Tumor bed volume (dose ≥ 60Gy) | ≤ 100 cm3 | 100 | 100 | 80 | 6.581 | 0.086 |
100.1–200 cm3 | 90 | 72 | 43 | |||
200.1–300 cm3 | 87 | 72 | 0 | |||
>300 cm3 | 74 | 54 | N/A | |||
Elective area volume (dose ≥ 50Gy) | ≤ 150 cm3 | 95 | 87 | 56 | 9.978 | 0.044 |
150.1–300 cm3 | 82 | 66 | 0 | |||
300.1–450 cm3 | 87 | 87 | N/A | |||
450.1–600 cm3 | 83 | 44 | N/A | |||
>600 cm3 | 66 | 33 | N/A |
Note: Statistically significant results in bold.
Abbreviations: p, significance level; R0, radical surgery; R1, non-radical microscopic surgery; R2, non-radical macroscopic surgery; RT, radiotherapy; CHT, chemotherapy; RT, radiotherapy; 2D, two-dimensional planning; 3D, three-dimensional planning; IMRT, planning with intensity-modulated radiation therapy.